A biotech licensing deal is worth the cash flows it is expected to deliver after accounting for timing, risk and the costs retained by each party. The announced maximum deal value answers a different question: how much could become payable if the agreement reaches every stated milestone? Those numbers can sit far apart. An upfront payment may arrive at closing, a regulatory milestone years later, a sales milestone never. Royalties may produce more value than the announced milestones, yet remain outside the headline figure. Valuing the agreement requires separating these components before combining them into a forecast.
The perspective matters too. A biotech company licensing out a drug receives payments but gives up some future economics and decision rights. The pharmaceutical company licensing it in acquires an opportunity, along with development spending and commercial risk. Neither side should treat the transaction as a simple exchange of cash for an approved product. Within biotech financial analysis and valuation, the task is to identify the rights transferred, forecast the cash flows attached to those rights and distinguish new value from value already included in the company’s balance sheet or pipeline model.
Separate the deal headline into economic components
Start with a payment schedule, rather than the press release total. Record what triggers each payment, when it could occur, which party controls the relevant activity and whether the amount covers one product or several. A development milestone for the first licensed molecule differs from a maximum milestone pool spread across a research platform. Likewise, a payment due on signing differs from one payable after closing conditions have been satisfied. Keep financing, research reimbursement and consideration for the licence in separate rows. Combining them makes a transaction look simpler, while making its economics harder to assess.
| Component | Economic purpose | Valuation treatment |
|---|---|---|
| Upfront payment | Initial consideration for the licensed rights | Include at the expected receipt date, subject to closing terms and retained obligations |
| Development and regulatory milestones | Payments for defined research, clinical or approval events | Weight each payment by its probability of achievement and discount for time |
| Commercial milestones | Payments linked to sales thresholds or other commercial events | Calculate within sales scenarios, using the contract’s exact thresholds |
| Royalties | A share of contractually defined net sales | Forecast by year, territory, rate tier and payment duration |
| Profit sharing | A share of defined profits, sometimes losses too | Model the agreed revenue and cost allocation, including spending before profitability |
| Research or supply funding | Payment for activities performed by the licensor | Match receipts against delivery costs; value the margin rather than gross receipts alone |
| Equity investment | Purchase of shares alongside the licence | Separate the financing from licence consideration and reflect the new shares |
Then define the asset being exchanged. Does the agreement cover worldwide rights, selected countries, one disease indication or every use of the molecule? Does it include follow-on compounds, combination products or access to manufacturing know-how? Retained rights need their own valuation, with costs allocated consistently across territories. The period over which those rights can generate cash also depends on the interaction between the contract and patents and regulatory exclusivity. A high royalty rate on a narrow territory with a short remaining commercial life may be worth less than a lower rate on broader, longer-lasting rights.
Upfront payments: immediate funding, with an economic price
An upfront payment has a clear advantage over a distant milestone: once received and available for use, it can fund the business without waiting for another development event. Its practical value depends on the obligations attached to it. A $100 million payment followed by $70 million of required clinical spending is different from $100 million received under a licence that transfers all future development costs to the partner. Map those outflows separately rather than describing the entire receipt as surplus cash. The payment’s effect on cash burn and runway should follow the revised development budget, not the headline receipt alone.
Funding can also change the company’s financing choices. A licence payment might allow a clinical readout to occur before the next equity raise, reducing dependence on an unfavourable share price. That benefit does not mean the company received free capital. It sold part of the asset’s potential return. Compare the partnered strategy with a credible alternative that includes the cost of independent development and the additional shares that financing could require. The relationship between partnership funding and share dilution belongs in the per-share model. Avoid adding a separate financing benefit if the alternative share counts already capture it.
Milestones: value each trigger, not the maximum pool
Development and regulatory milestones need individual event definitions. Trial initiation, completion, a positive result, application submission and approval are different triggers. A company may earn an early milestone even if the drug later fails. Conversely, approval in one country may leave a milestone for another territory untouched. Use the expected payment date, allowing for the interval between achieving the event and receiving cash. The underlying method is a forecast of future receipts and costs adjusted for uncertainty and time, consistent with the WIPO income approach to intellectual property valuation. The contract supplies the triggers; the analyst supplies and documents the assumptions.
The eplontersen agreement closed by AstraZeneca and Ionis on December 29, 2021 illustrates why separating milestone categories matters. Its announced terms included a $200 million upfront payment, up to $485 million in conditional payments following regulatory approvals and up to $2.9 billion in sales-related milestones. Those sales thresholds ranged from $500 million to $6 billion. Royalties were additional, with rates ranging from low double digits to the mid-twenties depending on the region, alongside territory-dependent cost sharing. The AstraZeneca announcement of the original eplontersen agreement therefore describes several economic streams, rather than a single amount available to Ionis at closing. This is a historical illustration of the disclosed structure, not a forecast of remaining payments.
Assign probabilities from the valuation date. If a milestone requires successful Phase 3 development followed by approval, its probability must reflect the path to both events. A probability conditional on reaching Phase 3 cannot be used as though Phase 3 has already been reached. The guide to clinical and regulatory success probabilities addresses that distinction in more detail. Also identify whether milestones are payable once per agreement, once per molecule or separately for each indication. A disclosed maximum covering several possible products should not be assigned entirely to the lead candidate unless the terms support that allocation.
Royalties: forecast the payment base before applying the rate
Net sales and the effective royalty rate
A royalty percentage has little meaning without its sales base. Forecast the partner’s contractually defined net sales, rather than multiplying a list price by every patient with the disease. Discounts, rebates, returns and other permitted deductions can change the amount on which payments are calculated. Combination products may require a further allocation between the licensed drug and other components. The commercial forecast therefore needs to connect patient uptake with realised revenue, using assumptions consistent with drug pricing, reimbursement and market access. Keep the distinction visible: the partner’s product sales, the royalty base and the licensor’s royalty receipts are separate lines.
The wording can be detailed. A January 29, 2007 agreement between the Salk Institute and Merrion Research defined permitted net sales deductions and included a formula for allocating combination-product sales. It also provided for an independent accountant to inspect records relevant to royalty and milestone payments. These provisions are visible in the SEC-filed Salk–Merrion licence agreement. The example shows why a short announcement cannot replace the underlying payment definitions. When reviewing another agreement, establish which deductions apply, whether sales to affiliates are treated differently and what reporting or audit rights support the calculation. Do not assume another contract uses the same wording.
Tiered royalties need an explicit calculation
Check whether royalty tiers apply only to incremental sales above each threshold or whether crossing a threshold changes the rate on a broader sales base. Consider a hypothetical incremental structure paying 10% on the first $500 million of annual net sales and 15% above that amount. At $800 million of net sales, the royalty is $95 million: $50 million on the first tier plus $45 million on the balance. The effective rate is 11.875%, not 15%. Applying the top rate to every dollar would overstate the payment by $25 million. Annual thresholds also need to reset in the correct period, with territories aggregated only where the agreement requires it.
Build an annual royalty curve and a defensible end date
Peak sales are one point on the forecast, not the forecast itself. Model launch timing, uptake, market share, pricing changes and eventual erosion. Begin with the eligible patient population and addressable market, then estimate how many patients receive the treatment in each year. Calculate royalties separately where regional rates or launch dates differ. If several indications contribute to sales, their development outcomes and uptake assumptions must remain identifiable. Otherwise, a model can accidentally assign full commercial revenue to an indication that has not yet established efficacy, then conceal the assumption inside a single peak-sales figure.
Read the royalty term with equal care. Establish the event that starts payment obligations and the conditions that end or reduce them, product by product and country by country where necessary. Check for rate reductions linked to competition, payments to other intellectual property owners or the loss of relevant protection. Treat undisclosed clauses as uncertainty, rather than silently assuming favourable terms. A longer sales forecast does not automatically justify a longer royalty forecast. Nor should a royalty stream receive a perpetual terminal value simply because the spreadsheet has an empty cell waiting for one. The cash must remain payable under a supportable interpretation of the agreement.
Profit sharing and cost commitments can change the result
A royalty model and a profit-sharing model require different cost treatment. Under a royalty arrangement, identify which development, supply or commercial costs the licensor still bears. Under profit sharing, reconstruct the contractual profit calculation and determine how losses are allocated before the product becomes profitable. Check who approves the budget, whether either party can pursue additional studies independently and what happens if one party stops contributing. Where the licensor supplies drug product, forecast revenue and production costs separately. The economics of biotech manufacturing and production capacity can turn an apparently attractive payment stream into a capital-intensive obligation.
The June 2025 BioNTech–Bristol Myers Squibb collaboration for BNT327 illustrates the distinction. The disclosed structure included a $1.5 billion upfront payment, $2 billion in anniversary payments scheduled from 2026 through 2028 and up to $7.6 billion in contingent development, regulatory and sales milestones. Adding those amounts produces a nominal $11.1 billion figure, before considering the collaboration’s operating economics. Subject to exceptions, the companies would share global profits and losses equally. The anniversary payments also depended on there being no prior termination by BMS. These conditions appear in the BMS second-quarter 2025 collaboration disclosure. Scheduled payments were therefore distinct from cash already received, while equal profit participation could not be modelled as a cost-free royalty on sales.
A worked licensing valuation
Consider a hypothetical biotech licensing out one drug. The announced consideration is up to $400 million before royalties, comprising $60 million upfront and three milestone payments. Assume the agreement has closed, the upfront is payable immediately and all future payments occur at the stated year-end. Use a 12% discount rate solely for illustration. The probabilities below are cumulative probabilities from today, already reflecting the path to each payment. This applies risk-adjusted net present value to the licensor’s contractual receipts. It does not value the entire drug franchise or prescribe a suitable discount rate for another asset.
Expected present value of a milestone = payment amount × probability of payment ÷ (1 + discount rate)years until payment.
| Payment | Nominal amount | Payment timing | Probability from today | Expected present value |
|---|---|---|---|---|
| Upfront | 60 | Now | 100% | 60.0 |
| Development milestone | 40 | Year 2 | 60% | 19.1 |
| Approval milestone | 100 | Year 5 | 30% | 17.0 |
| Sales milestone | 200 | Year 8 | 12% | 9.7 |
| Total before royalties and retained costs | 400 | Various | Various | 105.8 |
The $200 million sales milestone contributes only about $9.7 million of present value under these assumptions. Its 12% probability represents the chance of reaching the sales threshold from today, not the chance conditional on an already successful launch. For this example, assume approval and successful commercialisation share a 30% probability, and that the royalty stream has a present value of $200 million conditional on that outcome. Its probability-weighted value is $60 million. That figure is already discounted, so it should not be discounted a second time. Finally, assume retained deal-related spending has a probability-weighted present value of $25 million.
The resulting pre-tax deal value is approximately $140.8 million: $105.8 million of upfront and milestone receipts, plus $60 million of royalties, less $25 million of retained costs. This is the model’s expected value under its assumptions. It is neither a guaranteed return nor the amount payable in any one outcome. Taxes have been excluded from this illustration; an investment model should address them consistently with the chosen cash flows and discount rate. In a fuller model, annual scenarios would also align sales milestones, royalties and costs so that each payment follows the same underlying commercial outcome.
Value the licence from the buyer’s side too
The licensee begins with a different cash-flow claim. It receives the economics of the rights acquired, then pays for development, manufacturing, commercialisation and the licence itself. Upfront payments and milestones are outflows, royalties reduce the sales economics retained by the buyer. A positive valuation for the licensor does not establish that the buyer has overpaid. The buyer may have capabilities that improve launch execution or reduce incremental costs, while still requiring an adequate return on its spending. Test that proposition explicitly. A large partner’s participation is useful commercial evidence, but it does not replace analysis of the drug’s prospects or the price paid.
The buyer’s ability to stop development also deserves attention. An option-based collaboration may allow a company to fund research first and decide later whether to acquire fuller rights. Treat the exercise payment as conditional on that decision, rather than as committed consideration from the start. Later spending should follow the selected development path. The same logic applies when either party can opt out of cost sharing in exchange for different downstream economics. Model the alternative branches separately, including the payments and rights attached to each. Adding every possible option payment to every possible royalty stream can create a transaction that exists only in the spreadsheet.
Translate deal value into company and per-share value
Once an upfront payment has been received, it normally appears within the company’s cash position. Adding it again as future licence value counts the same money twice. In the worked example, the $140.8 million estimate includes the $60 million upfront. If that payment is already captured in the cash balance used for an equity valuation, the remaining contribution from the model is approximately $80.8 million. The bridge between enterprise value, cash and equity value must use one consistent valuation date. Update cash for subsequent receipts and spending where the most recent reported balance sheet predates the agreement.
Also remove the cash flows that the company transferred. A pre-deal model might have assigned the biotech all future product profits while charging it all development and launch costs. After licensing, replace those assumptions with the actual retained rights, payment streams and obligations. Do not keep the original full-product value and add the agreement on top. The value change is the difference between the partnered strategy and the previous strategy, adjusted for new evidence and financing needs. Where a partner buys shares, include the subscription proceeds and the additional shares consistently. The entire subscription is not automatically licence revenue or value created for existing shareholders.
Use comparable transactions as a cross-check
Comparable deals can test whether assumptions are plausible, but only after the transactions have been put on a similar footing. Compare development stage, evidence quality, geography, remaining protection and the costs retained by the seller. Separate upfront consideration from remote milestone pools, then examine downstream economics. A deal announced at $2 billion with $50 million upfront cannot be ranked against a $700 million agreement with $300 million upfront by headline size alone. This follows the distinction between income-based valuation and comparable transaction pricing in WIPO’s intellectual property valuation methods. Comparables provide a check on the model; they do not remove the need for one.
Platform collaborations require particular care. A maximum deal value covering several targets, optional programmes and replacement candidates is not directly comparable with a licence for one clinical asset. Assign value to the programmes actually included, then model further selections or option exercises as contingent opportunities. The distinction between biotech platforms and single-asset businesses matters because the number of possible products changes both the opportunity and the interpretation of the disclosed ceiling. If the payment allocation is confidential, use a range rather than inventing a precise allocation. Public announcements cannot establish a reliable industry royalty rate when the underlying rights and obligations differ.
Keep accounting revenue separate from economic value
Cash receipt, reported revenue and valuation measure different things. An upfront payment can improve liquidity even when the accounting treatment recognises revenue on another schedule. For contracts within its scope, IFRS 15 links revenue recognition to satisfying performance obligations and allocates transaction consideration among distinct promised goods or services. The IFRS 15 revenue recognition framework therefore provides a reason to inspect the accounting note rather than equating reported collaboration revenue with cash received. Establish the framework and treatment used by the company; do not assume every collaboration is accounted for identically. For valuation, track contractual receipts and associated expenditure directly. A large quarter of licence revenue should not be projected forward as though it were recurring product demand.
Test the assumptions that can move the valuation
A useful sensitivity analysis changes the assumptions most capable of altering the investment case. Test launch timing, milestone dates, commercial uptake, retained spending and royalty duration. Vary success probabilities separately from conditional sales estimates so the reason for each valuation change remains visible. A delay affects more than discounting: it may require further development funding, move milestone receipts and shorten the commercially attractive period. The guide to testing biotech valuation assumptions covers the broader process. For a licence, the analysis should also show which payments disappear entirely when a threshold is missed, rather than reducing every receipt by the same percentage.
Commercial milestones deserve scenario treatment because their payouts are discontinuous. A sales forecast just below a threshold produces no milestone; a slightly higher forecast may produce a large payment. Applying the contract to each sales scenario captures that difference. Include scenarios in which the product reaches market but performs poorly, particularly where competing treatments and standards of care could restrict adoption. Clinical success alone does not establish that a high sales threshold will be reached. Keep the risk adjustments traceable too. If development failure has already been reflected through explicit probabilities, explain what additional risks the discount rate captures instead of adding another unexplained failure allowance.
Build a deal file that can be updated
Maintain a compact record of the agreement alongside the financial model. Start with the announcement, retrieve the relevant securities filing and inspect the agreement or exhibits where public. Read later amendments before assuming the original terms still apply. The approach to researching biotech through financial filings and other primary records is particularly useful when a short announcement omits termination provisions or cost commitments. Record what is disclosed and what remains unknown. Confidential terms justify valuation ranges, not fabricated precision. A model should make it possible for another reader to distinguish a contractual fact from an analyst’s estimate without reconstructing the entire research process.
- Rights: products, territories, indications and retained opportunities.
- Payments: amounts, triggers, expected dates and whether each has already been received.
- Downstream economics: royalty base, tiers, duration, reductions or profit-sharing definitions.
- Obligations and control: spending commitments, budget authority, options and termination consequences.
- Model assumptions: probabilities, sales scenarios, costs, taxes and the valuation date.
Update the affected rows when new evidence arrives. If a development milestone is achieved, replace its uncertain forecast with the actual payment or receivable and reassess the probabilities of later events. If the partner changes the development plan, revise timing and spending rather than moving only the launch year. If rights return, remove unsupported future partner payments and estimate the costs and opportunities attached to regaining control. Preserve the previous model version. The resulting audit trail shows whether a valuation changed because the contract changed, the evidence improved or the analyst revised an assumption.